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Abstract 
Background: The aims of this study were to investigate whether circulating irisin is associated with favorable meta‑
bolic parameters and how the association differs according to body composition in humans.
Methods: A total of 424 subjects (233 men and 191 women), aged 23–73 years (mean age 47.1 years), were enrolled 
from the Seoul Metro City Diabetes Prevention Program. Body composition was determined using an impedance 
body composition analyzer, and serum irisin level was measured using a commercial kit.
Results: Serum irisin was correlated with favorable metabolic parameters including less obese, lower blood pressure 
and glucose levels and healthy lipid parameters. The skeletal muscle mass to visceral fat area ratio (SVR) was posi‑
tively correlated with the serum irisin concentration (r = 0.10, P = 0.04). When the study subjects were divided into 
tertiles according to their SVR, serum irisin was correlated with favorable metabolic phenotypes in those subjects in 
the upper tertile. However, there were no such correlations in the lower tertile. In addition, serum irisin was inversely 
related to pre‑diabetes/type 2 diabetes (T2D) independent of other risk factor for T2D and insulin resistance [OR (95 % 
CI); 0.66 (0.49–0.90), P = 0.009].
Conclusions: The compositions of skeletal muscle and visceral fat play key roles in the association between circulat‑
ing irisin and a patient’s metabolic phenotype.
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Background
Adipose tissue is an active endocrine organ. Recent stud-
ies have suggested that liver and bone regulate whole 
body energy homeostasis through their production of 
hepatokines [1] and osteocalcin [2], respectively. Skeletal 
muscle also communicates with other organs through its 
secretion of hormones called myokines, which are mostly 
released into the blood stream during or immediately 
after physical activity [3–6].
Irisin is a novel myokine that is, proteolytically pro-
cessed from the product of the FNDC5 gene. Both exer-
cise and the peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC1α) induce irisin expression. 
Irisin induces the browning of subcutaneous adipocytes 
and thermogenesis by increasing the level of uncoupling 
protein 1 (UCP1) level. In doing so, irisin mediates the 
beneficial effects of exercise on energy metabolism. In 
one animal study, 3  weeks of wheel running increased 
plasma irisin levels in mice, and adenoviral FNDC5 over-
expression in high-fat diet-induced obese mice showed 
increased oxygen consumption, body weight loss, 
improved glucose tolerance, and lower fasting insulin 
compared to those of diet-induced obese control mice 
[3].
However, the associations between circulating iri-
sin and physical activity or glucose metabolism are still 
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elusive in humans. Initial reports demonstrated a two-
fold increase in circulating irisin levels after 10  weeks 
of endurance training in healthy adults [3]. However, a 
subsequent study found that muscle FNDC5 mRNA 
expression was only increased in elderly subjects after 
endurance training, and not in younger subjects [7]. In 
a cohort of 118 patients, the FNDC5 mRNA expression 
in muscle was not correlated with glucose homeosta-
sis [7]. Another study, however, found that serum irisin 
level was lower in patients with type 2 diabetes (T2D) 
than it was in subjects with normal glucose tolerance [8, 
9]. Serum irisin was also found to be negatively corre-
lated with fat mass, fasting glucose and dyslipidemia but 
not with other adipokines. Furthermore, irisin decreased 
during an oral glucose tolerance test (OGTT) in sub-
jects with all degrees of glucose tolerance [10]. In con-
trast, another report showed that baseline irisin level 
was positively correlated with body mass index (BMI), 
blood pressure, fasting glucose, triglycerides, and insulin 
resistance [11].
Therefore, the aims of this study were to investigate 
whether circulating irisin is independently associated 
with favorable metabolic parameters including glucose 
tolerance and to determine whether the association 
between circulating irisin and metabolic profile is dif-
ferent from body composition which was determined by 
skeletal muscle mass to visceral fat area ratio (SVR), one 
of the two sources of circulating irisin.
Methods
Study population
A cross-sectional study was performed involving 424 
subjects (233 men and 191 women) aged 23–73  years 
(mean age 47.1  years). The subjects were enrolled in 
the second year of the Seoul Metro City Diabetes Pre-
vention Program (SMC-DPP) between August and 
December 2010. The SMC-DPP is a community-based 
follow-up program that is composed of three groups, 
including healthy people and subjects with pre-diabetes 
or T2D. The participants were recruited from six com-
munity health centers in Seoul. After excluding partici-
pants with previously diagnosed diabetes or anti-diabetic 
medications, a 75 g-OGTT was conducted in the remain-
ing participants. The participants were classified into 
groups based on the result of the OGTT, in accordance 
with the diagnostic criteria from the American Diabetes 
Association. Subjects with a history of type 1 diabetes, 
secondary diabetes, or other problems such as major car-
diovascular disease, hemodialysis, and malignancy were 
excluded. This study was approved by the Institutional 
Review Board at Kangbuk Samsung Hospital. Informed 
written consent was obtained from each subject.
Anthropometric and laboratory assessments
Blood pressure was measured in duplicate after at least 
5  min of rest, and the results were averaged. BMI was 
expressed as body weight in kilograms divided by the 
square of height in meters (kg/m2). Body composition 
was determined using the multi-frequency impedance 
body composition analyzer with eight-point tactile elec-
trodes (InBody 720; Biospace, Seoul, Korea). The analyzer 
measured resistance at specific frequencies (1, 5, 50, 250, 
500 kHz, and 1 MHz) and reactance at specific frequen-
cies (5, 50, and 250 kHz). The following other measure-
ments were also made: skeletal muscle mass (kg), body 
fat mass (kg), percent body fat (%), waist-hip ratio and 
visceral fat area (%). Additional data used in the analysis 
included arm circumference, arm muscle circumference, 
and basal metabolic rate.
Blood samples were collected after overnight fast-
ing. Plasma glucose was determined by the hexokinase 
method using a Beckman glucose analyzer II (Beckman 
Instruments, Fullerton, CA, USA). High-performance 
liquid chromatography was used to measure HbA1c 
(Variant II, Bio-Rad Laboratories, Hercules, CA, USA). 
Total cholesterol, triglyceride, HDL cholesterol, and 
LDL cholesterol levels were determined by an enzymatic 
colorimetric assay using an autoanalyzer (Siemens, Tar-
rytown, NY, USA). High-sensitivity C-reactive protein 
levels were measured by immune-nephelometric assay 
using a BNII nephelometer (Dade Behring, Deerfield, IL, 
USA). Serum insulin level was measured using an immu-
noradiometric assay (Biosource, Belgium).
The homeostasis model assessment of insulin resist-
ance (HOMA-IR) was calculated as the product of 
fasting serum insulin (mU/L) and FPG (mmol/L) con-
centrations, divided by 22.5. HOMA-B  % was calcu-
lated using (20  ×  fasting serum insulin)/(FPG  −3.5), 
and used to represent ß-cell function [12]. In this study, 
T2D was defined by the presence of one of the follow-
ing: (1) FPG ≥7.0 mmol/L; (2) treatment with oral hypo-
glycemic agents or insulin therapy; or (3) 2  h post-load 
glucose  ≥11.1  mmol/L. Normal glucose tolerance was 
defined as FPG  <5.6  mmol/L and 2  h post-load glu-
cose  <7.8  mmol/L. Pre-diabetes is comprised of two 
different categories of impaired fasting glucose and 
impaired glucose tolerance. Impaired fasting glucose was 
defined as FPG of 5.6–6.9  mmol/L, while impaired glu-
cose tolerance was defined as 2-hour post-load glucose of 
7.8–11.0 mmol/L [13]. Metabolic syndrome was defined 
using the criteria proposed by the National Cholesterol 
Education Program Adult Treatment Panel III [14].
The serum irisin level was measured using an enzyme 
linked-immunosorbent assay (ELISA) commercial 
kit (AdipoGen, Korea). The intra-assay coefficients of 
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variation (CVs) for irisin ranged between 4.86 and 8.19 %, 
and inter-assay CVs ranged from 8.03 to 9.72 %.
Statistical methods
All data are presented as means ±  SDs or proportions, 
except for skewed variables, which are presented as medi-
ans (interquartile range, 25–75  %). One-way ANOVA, 
followed by Tukey’s posthoc test, and the Kruskal–Wal-
lis test were used to compare the differences between 
the irisin tertiles. A linear-by-linear association χ2-test 
was used to perform trend analysis between the tertiles. 
The spearman correlation coefficients were calculated 
to compare the irisin and clinical and laboratory meas-
urements. Multiple logistic regression analysis was used 
to calculate an odds ratio (OR) for the presence of pre-
diabetes/T2D. The results of the analyses are presented 
as OR with a 95  % confidence interval (CI). All statisti-
cal analyses were performed using PASW version 18.0 
(SPSS, Chicago, IL, USA). P values <0.05 were considered 
statistically significant.
Results
Baseline characteristics of the study subjects according 
to serum irisin tertile are shown in Table  1. The mean 
age decreased from the lower to upper serum irisin ter-
tiles and there was no difference by sex. Waist circum-
ference was inversely correlated with serum irisin level 
(P  =  0.04). In addition, HOMA-IR decreased as serum 
irisin level increased. Serum irisin concentrations were 
significantly higher in subjects with normal glucose tol-
erance compared to subjects with pre-diabetes or T2D 
(2.16  ±  0.59  μg/mL in normal glucose tolerance and 
1.77  ±  0.91  μg/mL in pre-diabetes or T2D, P  <  0.001; 
data not shown). The irisin levels were also significantly 
higher in subjects without metabolic syndrome com-
pared to those with metabolic syndrome (1.91 ± 0.92 μg/
mL without metabolic syndrome and 1.78 ± 0.80 μg/mL 
with metabolic syndrome, P = 0.03; data not shown).
With regard to body composition, there was a strong 
correlation between visceral fat area and skeletal mus-
cle mass (r =  0.25, P  <  0.001; data not shown). Skeletal 
muscle mass adjusted for visceral fat area was positively 
correlated with serum irisin concentration (r  =  0.10, 
P = 0.042). However, there were no correlations for the 
total fat mass or percentage of body fat (Table 2).
The study subjects were then divided into tertiles 
according to the SVR. In the upper tertile, Serum irisin 
was inversely correlated with age, obesity, diastolic blood 
pressure, glucose intolerance, HOMA-IR, and dysmeta-
bolic lipid profile. However, there were no such favora-
ble correlations with serum irisin in subjects in the lower 
tertile. In contrast, in these subjects, there was a posi-
tive correlation between the serum irisin and glycated 
hemoglobin levels (Table  3). In addition, we used waist 
circumference as an estimate for visceral abdominal fat 
instead of visceral fat area by InBody and divided the 
subjects into tertiles according to skeletal muscle mass 
to waist circumference ratio. Similar with the result 
form to skeletal muscle mass to visceral fat area tertiles, 
serum irisin level was inversely correlated with unhealthy 
metabolic profiles, especially in subjects in the upper ter-
tile. However, there were no favorable correlations with 
serum irisin in subjects in the lower tertile (Additional 
file 1: Table S1).
Finally, we determined whether serum irisin level was 
independently associated with the presence of abnormal 
glucose tolerance. In this analysis, log transformed serum 
irisin was inversely associated with pre-diabetes/T2D 
independent of age, sex, BMI, waist circumference, sys-
tolic blood pressure, triglycerides, and HDL cholesterol 
[OR (95  % CI); 0.60 (0.45–0.79), P  <  0.001; model IV]. 
Further adjustment of HOMA-B  % [OR (95  % CI); 0.55 
(0.41–0.75), P < 0.001; model V] or HOMA-IR [OR (95 % 
CI); 0.66 (0.49–0.90), P < 0.01; model VI] did not affect 
this association between serum irisin and pre-diabetes/
T2D (Table 4).
Discussion
In the current study, higher circulating irisin was corre-
lated with favorable metabolic profiles, including waist 
circumference, blood pressure, blood glucose level, lipid 
parameters, and HOMA-IR, a marker of insulin resist-
ance. With regard to glucose tolerance, circulating irisin 
was inversely correlated with the presence of pre-diabe-
tes/T2D, independent of other well-known risk factors 
for T2D, including age, sex, BMI, waist circumference, 
systolic blood pressure, and atherogenic lipid profiles. In 
particular, serum irisin was still protective against abnor-
mal glucose tolerance after further adjusting for HOMA-
B % or HOMA-IR.
To date, the biological function of irisin has been 
largely unknown, with contradictory results in human 
studies [3, 7–11, 15, 16]. In agreement with our results, 
serum irisin level was found to be significantly lower in 
patients with new-onset T2D compared with subjects 
with normal glucose tolerance, and increased irisin level 
was associated with reduced risk for T2D independent of 
BMI, renal function, diastolic blood pressure, HOMA-
IR, and triglyceride levels [8]. In addition, a previous 
study found that circulating irisin was negatively corre-
lated with BMI, percent fat mass, and waist to hip ratio 
and positively correlated with insulin sensitivity. Moreo-
ver, circulating irisin concentration was decreased sig-
nificantly in subjects with T2D [15]. In contrast, another 
report showed results in striking contrast to our results 
[11]. In that report, baseline irisin level was significantly 
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higher in subjects with metabolic syndrome compared to 
subjects without metabolic syndrome and was positively 
correlated with unhealthy metabolic phenotype. In addi-
tion, irisin was independently associated with HOMA-IR 
and ten-year risk of cardiovascular disease after adjust-
ment for confounders. Therefore, it is possible that irisin 
secretion is increased in adipose/muscle tissue and/or 
there is a compensatory hyper-secretion of irisin in order 
to overcome irisin resistance in obese subjects.
Low SVR may represent a state of sarcopenic obesity, 
which has been reported to be associated with insulin 
resistance and metabolic syndrome [17–19]. In addi-
tion, a previous study demonstrated that lower SVR was 
independently associated with the presence of meta-
bolic syndrome and arterial stiffness [19]. In our study, 
circulating irisin was not correlated with skeletal mus-
cle mass (r  =  −0.06, P  =  0.20); however, visceral fat 
area was inversely correlated with circulating irisin level 
(r = −0.13, P  <  0.01). Subjects were then divided study 
into tertiles according to SVR. Although circulating iri-
sin was inversely correlated with BMI, waist circumfer-
ence, unhealthy metabolic profiles, and insulin resistance 
in the total subjects, the correlations were quite differ-
ent according to SVR tertile. That is, although irisin level 
was strongly and inversely correlated with the aforemen-
tioned parameters in subjects in the upper tertile, as SVR 
decreased, the inverse correlations weakened. In the lower 
tertile, there were no favorable effects of irisin on meta-
bolic profile. In contrast, there was no difference in serum 
irisin levels between the lower tertile and upper tertile 
(data not shown). We further analyzed the correlation 
between serum irisin and metabolic parameters accord-
ing to the presence of metabolic syndrome (Additional 
file  1: Table S2). As a result, serum irisin was inversely 
Table 1 Baseline characteristics according to serum irisin tertile
Data are expressed as means ± SDs, medians ± inter-quartile ranges or frequency (%)
a,b The same letters indicate no statistical significance
Total (n = 424) 1st tertile (n = 142) 2nd tertile (n = 141) 3rd tertile (n = 141) P
Irisin (μg/mL) 1.71 (1.44, 2.02) 1.35 (1.20, 1.45) 1.72 (1.62, 1.81) 2.30 (2.04, 2.68) <0.001
Age (year) 47.1 (9.2) 48.7 (8.5)a 47.5 (8.7)ab 45.2 (10.0)b 0.005
Male (%) 233 (55.0) 88 (62.0) 71 (50.4) 74 (52.3) 0.11
Body mass index (kg/m2) 24.7 (3.5) 25.1 (2.9) 24.6 (3.9) 24.3 (3.6) 0.15
Waist circumference (cm) 84.3 (9.7) 85.8 (7.7)a 84.2 (10.7)ab 82.9 (10.4)b 0.041
Systolic blood pressure (mmHg) 121.3 (14.1) 123.1 (14.1) 120.6 (14.1) 120.1 (14.0) 0.18
Diastolic blood pressure (mmHg) 75.8 (10.2) 77.0 (10.8) 76.4 (9.7) 74.1 (9.8) 0.05
OGTT (mmol/L)
0 min 6.4 (1.9) 6.7 (2.0) 6.3 (1.5) 6.3 (2.0) 0.13
120 min 8.6 (3.8) 8.8 (4.1)ab 8.0 (2.7)a 9.3 (4.4)b 0.041
A1c (%) 6.0 (1.3) 6.0 (1.1) 5.9 (1.0) 6.2 (1.6) 0.06
HOMA‑IR 2.26 (1.61, 3.24) 2.50 (1.83, 3.26)a 2.30 (1.79, 3.23)a 1.90 (1.25, 3.40) 0.001
HOMA‑B (%) 73.2 (52.4, 97.2) 74.2 (52.3, 99.1) 74.4 (54.7, 98.0) 72.2 (46.9, 92.9) 0.47
Type 2 diabetes (%) 92 (21.7) 30 (21.1) 29 (20.6) 34 (24.1) 0.54
Pre‑diabetes/type 2 diabetes (%) 333 (785) 129 (90.8) 118 (83.7) 86 (61.0) <0.001
Total cholesterol (mmol/L) 4.96 (0.90) 5.11 (0.85)a 5.00 (0.86)ab 4.77 (0.96)b 0.005
Triglyceride (mmol/L) 1.74 (1.25, 2.59) 1.45 (1.01, 2.26)a 1.25 (0.98, 1.70)a 1.08 (0.76, 1.44) <0.001
HDL cholesterol (mmol/L) 1.31 (0.32) 1.27 (0.27) 1.34 (0.37) 1.34 (0.29) 0.09
LDL cholesterol (mmol/L) 3.03 (0.85) 3.11 (0.81) 3.05 (0.81) 2.93 (0.93) 0.22
High‑sensitivity CRP (mg/L) 0.04 (0.02, 0.11) 0.04 (0.02, 0.09) 0.04 (0.02, 0.11) 0.05 (0.03, 0.11) 0.07
  Metabolic syndrome (%) 155/414 (37.4) 59/137 (43.1) 54/138 (39.1) 42/139 (30.2) 0.027
Table 2 Correlation of irisin with Inbody measurements
r P
Waist circumference −0.11 0.019
Waist to hip ratio −0.15 0.002
Skeletal muscle mass −0.06 0.20
Total fat mass −0.02 0.69
Body fat % 0.02 0.67
Visceral fat area −0.13 0.009
Skeletal muscle mass/visceral fat area 0.10 0.042
Arm circumference −0.10 0.048
Arm muscle circumference −0.09 0.08
Basal metabolic rate −0.06 0.22
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correlated with BMI, waist circumference, fasting glucose, 
HbA1c, total cholesterol, triglyceride, LDL cholesterol, 
and HOMA-IR in subjects without metabolic syndrome. 
However, these correlations did not exist in subjects with 
metabolic syndrome. Therefore, it is possible that the 
function of irisin is more important than is the circulat-
ing irisin level per se with regard to metabolic effects, and 
body composition of skeletal muscle and visceral fat areas 
play key roles in its functionality. That is, circulating iri-
sin appears to be dysfunctionally altered in subjects with 
lower skeletal muscle mass and higher visceral fat.
This study has several limitations. First, it was based 
on a cross-sectional analysis; thus, it is not possible to 
determine causal relationships. In particular, FNDC5/
irisin is known to be released into circulation mainly dur-
ing or immediately after physical activity, and it would 
be valuable to determine the association between incre-
mental circulating irisin levels after exercise and its meta-
bolic effects. Second, we did not measure FNDC5 gene 
expression from muscle or adipose tissue. We also did 
not measure the levels of other circulating myokines or 
adipokines, which may co-secrete from muscle or adi-
pose tissue. Third, the Inbody measurement system is not 
a gold standard tool to assess body composition. How-
ever, it was reported that visceral fat measurements by 
InBody 720, which is an identical method to that used 
in our study, are highly correlated with those measured 
by abdominal CT scan, a gold standard method to meas-
ure visceral abdominal fat (r = 0.759) [20]. Lastly, it was 
reported that commercial ELISA kits could be not an 
accurate measure of serum irisin levels due to non-spe-
cific cross-reactivity [21]. For instance, median irisin 
levels in our study were somewhat higher (1.71  μg/mL) 
than those measured in other studies (0.76–1.03 μg/mL) 
using identical ELISA kits [10, 22]. Therefore, our results 
should be confirmed with other more valid methods to 
measure serum irisin levels.
Conclusions
Circulating irisin is correlated to favorable metabolic 
profile, including reduced obesity, lower blood pressure 
and lower glucose levels, healthy lipid parameters, and 
increased insulin sensitivity. Irisin was also inversely 
associated with the diagnosis of pre-diabetes or T2D, 
independent of other well known risk factors for T2D. 
Table 3 Correlation with serum irisin according to skeletal muscle mass to visceral fat area tertile
* P < 0.05, ** P < 0.01, *** P < 0.001
Total (n = 424) Lower tertile (n = 142) Middle tertile (n = 141) Upper tertile (n = 141)
Age −0.17** −0.06 −0.18* −0.17*
Body mass index −0.10* 0.05 −0.06 −0.22**
Waist circumference −0.11* 0.01 −0.10 −0.20*
Systolic blood pressure −0.11* 0.10 −0.20* −0.14
Diastolic blood pressure −0.14** 0.10 −0.22** −0.25**
OGTT (0 min) −0.25*** 0.13 −0.21* −0.52***
OGTT (120 min) −0.00 0.11 −0.09 −0.07
A1c −0.05 0.17* −0.06 −0.27**
HOMA‑IR −0.18*** 0.14 −0.20* −0.37***
HOMA‑B % 0.01 0.02 0.04 0.04
Total cholesterol −0.16** 0.02 −0.14 −0.27**
Triglycerides −0.21*** 0.09 −0.25** −0.37***
HDL cholesterol 0.13** −0.02 0.13 0.21*
LDL cholesterol −0.10 −0.03 −0.09 −0.20*
High‑sensitivity CRP 0.12* 0.16 0.11 0.14
Table 4 Multiple logistic regression analysis of  log trans-
formed serum irisin for pre-diabetes or T2D
Model I: no adjustment
Model II: Model I + adjustment for age and sex
Model III: Model II + adjustment for body mass index, waist circumference, 
systolic blood pressure
Model IV: Model III + adjustment for triglyceride, HDL cholesterol
Model V: Model IV + adjustment for HOMA-B %
Model VI: Model IV + adjustment for HOMA-IR
OR (95 % CI) P
Model I 0.49 (0.37–0.64) <0.001
Model II 0.55 (0.42–0.72) <0.001
Model III 0.56 (0.42–0.74) <0.001
Model IV 0.60 (0.45–0.79) <0.001
Model V 0.55 (0.41–0.75) <0.001
Model VI 0.66 (0.49–0.90) 0.009
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However, the function of irisin is more important than is 
the circulating irisin level, with regard to the metabolic 
effects and body composition of skeletal muscle and vis-
ceral fat play key roles in its functionality.
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